AstraZeneca plc with ticker (LON:AZN) now has a potential upside of 38.4% according to JP Morgan.
AZN.L
JP Morgan set a target price of 14,000 GBX for the company, which when compared to the AstraZeneca plc share price of 10,114 GBX at opening today (15/11/2024) indicates a potential upside of 38.4%. Trading has ranged between 9,461 (52 week low) and 13,388 (52 week high) with an average of 2,372,380 shares exchanging hands daily. The market capitalisation at the time of writing is £156,025,898,582.
AstraZeneca PLC is a science-led biopharmaceutical company. It discovers, develops, and commercializes prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its biopharmaceuticals products include Farxiga, Crestor, Breztri and others. Its investigational vaccine candidate IVX-A12, which targets both respiratory syncytial virus and human metapneumovirus. Its oncology candidate includes FPI-2265 targeting prostate specific membrane antigen for metastatic castration resistant prostate cancer, which is in a Phase II trial. It also discovers, develops, and manufactures T-cell receptor therapies. Its Eneboparatide is an investigational therapeutic peptide.
AstraZeneca plc 38.4% potential upside indicated by JP Morgan
- Written by: Charlotte Edwards
Find more news, interviews, share price & company profile here for:
AstraZeneca's Imfinzi has received FDA approval as a groundbreaking treatment for muscle-invasive bladder cancer, significantly improving patient outcomes in clinical trials.
AstraZeneca is set to transform cancer treatment by acquiring EsoBiotec, a leader in in vivo cell therapies that promise quicker, more effective patient care.
The MATTERHORN Phase III trial reveals promising results for AstraZeneca's Imfinzi in enhancing event-free survival for patients with early-stage gastric cancer.
AstraZeneca and Daiichi Sankyo's Datroway gains FDA approval, offering a new treatment option for specific metastatic breast cancer cases.
AstraZeneca's Tagrisso gains EU approval for treating advanced NSCLC, showing significant efficacy in reducing disease progression in key trials.
